Sequencing Therapies in Renal Cell Carcinoma
Presented by Sumanta Kumar Pal, MD, and Kathleen Burns, AGACNP-BC, OCN®
City of Hope Comprehensive Cancer Center, Duarte, California
Presenters’ disclosures of conflicts of interest are found at the end of this article.
J Adv Pract Oncol 2019;10(3):268–271 |
© 2019 Harborside™
Sumanta Kumar Pal, MD, and Kathleen Burns, AGACNP-BC, OCN®, explained the use of tyrosine kinase inhibitors in the adjuvant setting in patients with advanced renal cell carcinoma, as well has how to best utilize immunotherapy in this setting.
For access to the full length article, please sign in